Loading
Latest filing published 07 May 2026 for 엔지켐생명과학, €2.8M.
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
이수민 (chief executive) discloses dealings in 2 companies, chiefly 현대자동차 and 엔지켐생명과학. In total, 3 filings cover trades dated from 2 February 2026 to 4 May 2026.
The open-market side counts 2 purchases for €2.8M alongside 1 sale. No amount is published for 1 filing, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price.
The latest filing, published on 7 May 2026, reports an open-market purchase of €2.8M in 엔지켐생명과학. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations